RxDoctor Payments Data

Thomas Leopold, MD

Cardiovascular Disease · South Plainfield, NJNPI 1902898737

Payments from drug & device makers

$415in general payments, 2019–2025

Across 21 payments — averaging $19.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$125
  • Sanofi-aventis U.S. LLC$49
  • Johnson & Johnson$40
  • Boehringer Ingelheim$39
  • Medtronic$30
  • Amgen$27
  • plus $105 from 6 others

What the payments were for

  • Consulting fees$307%
  • Speaking & faculty fees$12530%
  • Food & beverage$26063%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$415 in reported general payments places this provider in the 15th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$109,047
Medicare patients
1,487
Services billed
2,621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban123$147,735
XareltoRivaroxaban47$48,837
MultaqDronedarone Hcl34$41,875
FarxigaDapagliflozin Propanediol25$25,953
EntrestoSacubitril/Valsartan22$18,115
BrilintaTicagrelor15$14,137
Praluent PenAlirocumab20$9,219
Metoprolol Succinate263$5,345
Atorvastatin Calcium206$2,383
Nebivolol Hcl25$1,688
Amlodipine Besylate253$1,611
Nifedipine ErNifedipine25$1,457
Diltiazem 24hr Er (Cd)Diltiazem Hcl32$1,303
Ezetimibe58$1,266
Valsartan38$1,178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11$147,735123 claims
Johnson & JohnsonXarelto$40$48,83747 claims
Sanofi-aventis U.S. LLCMultaq$49$41,87534 claims
NovartisEntresto$18$18,11522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in South Plainfield

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →